The impressive spreading of VSV-CD133 in tumor tissue and the significant prolongation of survival after systemic administration therefore warrant further testing of VSV-CD133 toward applications in cancers of the gastrointestinal tract with CD133-positive CSCs being involved. This evidence concerns the gene PROM1 and cancer.